Molecular Diagnostics
British Journal of Cancer (2007) 96, 1904–1907. doi:10.1038/sj.bjc.6603816 www.bjcancer.com
Published online 22 May 2007
Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis
A Matakidou1, R el Galta1, M F Rudd1, E L Webb1, H Bridle2, T Eisen2, R S Houlston1 and the GELCAPS Consortium3
- 1Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
- 2Department of Oncology, University of Cambridge, Cambridge, UK
Correspondence: Professor RS Houlston, Section of Cancer Genetics, Brookes Lawley Building, Institute of Cancer Research, Surrey SM2 5NG, UK. E-mail: richard.houlston@icr.ac.uk
3List of GELCAPS Consortium collaborators available on request
Revised 4 April 2007; Accepted 1 May 2007; Published online 22 May 2007.
Abstract
The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a wide variety of cancer types. To determine whether Gly388Arg is a marker for lung cancer prognosis, we genotyped 619 lung cancer patients with incident disease and examined the relationship between genotype and overall survival. While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
Keywords:
lung cancer, FGFR4, Gly388Arg polymorphism, prognosis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis
Prostate Cancer and Prostatic Diseases Original Article
British Journal of Cancer Scientific Correspondence
